Hims & Hers Health (HIMS) Morgan Stanley Technology, Media & Telecom Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Morgan Stanley Technology, Media & Telecom Conference 2026 summary
2 Mar, 2026Strategic evolution and vision
Initial focus was on making treatment for stigmatized conditions accessible and raising consumer awareness, evolving to include personalized treatments and broader capabilities.
Significant investments in technology and CapEx enabled rapid expansion into new specialties and improved operational efficiency.
Leveraging data and insights from over 2.5 million subscribers to enhance personalized care and outcomes.
Future strategy emphasizes deepening personalization, leveraging technology, expanding partnerships, and international growth.
Vision is to become the default brand for health and wellness within three to five years.
Growth initiatives and market expansion
Expanded into multi-condition offerings and launched three complex specialties in six months, including low testosterone, menopausal support, and diagnostics.
Acquisitions like YourBio Health and Eucalyptus support diagnostics and international expansion.
Each new specialty is expected to reach a $100 million+ run rate, with ambitious targets of $6.5 billion revenue and $1.3 billion EBITDA by 2030.
International strategy is driven by strong domestic cash flow, successful acquisitions, and market learnings, aiming for at least $1 billion in international revenue in the next few years.
International markets are expected to follow a similar margin expansion curve as the U.S., supported by operational expertise and capital allocation.
Marketing, brand, and consumer engagement
Shifted to broader brand education, resulting in a 7-point year-over-year improvement in marketing efficiency.
Investments in brand and proactive health education are expected to yield long-term efficiency gains.
Super Bowl ad and other campaigns have driven increased traffic and engagement.
Cross-sell opportunities and diagnostics are expected to further improve marketing efficiency and consumer retention.
Latest events from Hims & Hers Health
- 2025 revenue up 59% to $2.35B, with strong subscriber and specialty growth, and robust 2026 outlook.HIMS
Q4 202524 Feb 2026 - Q2 revenue up 52% to $315.6M, net income $13.3M, strong subscriber and margin growth.HIMS
Q2 20242 Feb 2026 - Personalized, tech-driven healthcare and GLP-1s fuel rapid growth and operational gains.HIMS
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Directors were elected, auditor ratified, and executive pay approved; results to be filed.HIMS
AGM 20241 Feb 2026 - Q3 2024 revenue up 77% to $401.6M, net income $75.6M, and 2M subscribers.HIMS
Q3 202417 Jan 2026 - 2024 revenue up 69% to $1.5B, net income $126M, 2025 guidance set at $2.3–$2.4B revenue.HIMS
Q4 20247 Jan 2026 - Q1 revenue up 111% to $586M, with strong subscriber growth and raised full-year guidance.HIMS
Q1 202520 Dec 2025 - Personalization, technology, and vertical integration fuel strong growth and margin expansion.HIMS
Morgan Stanley Technology, Media & Telecom Conference17 Dec 2025 - Shareholders to vote on board, auditor, and executive pay amid strong growth and governance.HIMS
Proxy Filing1 Dec 2025